At the NORD Rare Disease Impact Award Ceremony, we talked with David Shapiro, M.D., chief medical officer at Intercept Pharmaceuticals about his company's achievements in the past year, including the approval of Ocaliva (obeticholic acid) for the treatment of patients with primary biliary cholangitis (PBC).
As Dr Shapiro explains in this interview, Intercept has grown from a small research team to a full fledged pharmaceutical company providing new treatment options for people in need.
PBC is a rare autoimmune liver disease that destroys the medium size bile ducts within the liver. Symptoms include abdomen pain, musculoskeletal pain, jaundice, edema, ascites, osteoporosis, elevated cholesterol and hypothyroidism.
The incidence of the disease has been estimated as 4.5 per 100,000 people.